The Indian pharmaceutical and biotech sectors may see more M&A activity this year with rumours that GSK, Sanofi Aventis and Merck KGaA are on the look out for potential deals.
French drug major Sanofi Aventis is in talks about taking over market leading Brazilian generics firm Medley, according to reports the country’s Valor Economico newspaper.
New Sanofi Aventis chief Christopher Viebacher has virtually ruled out major acquisitions, eschewing the trend started by Pfizer’s $68bn (€53bn) swoop for Wyeth in favour of an anti-mega merger stance like that adopted by UK rival GSK.
The strained relationship between Genentech and Roche has been revealed in a SEC filing, which details their differing valuations and accusations of misleading financial models.
Australian packaging company Amcor is in talks with mining giant Rio Tinto about buying part of the latter’s Alcan Packaging Division, confirming speculation that emerged late last year.
Roche has stepped up its pursuit of Genentech, launching a hostile bid of $42bn after growing frustrated with the lack of progress over the past six months.
Pfizer’s $68bn swoop for Wyeth looks set to start an epidemic of merger madness according to comments by Frost & Sullivan (F&S) analyst Shabeer Hussain.
Pfizer has confirmed it has entered into an agreement to buy Wyeth in a deal worth $68bn, which it hopes will strengthen its position in anticipation of a challenging few years.
Sanofi-Aventis is to sell its liquid drug manufacturing plant in Colomiers, southwest France, to industry specialist Unither for an as yet undisclosed sum.
King Pharmaceuticals’ $1.6bn (€1.2bn) acquisition of Alpharma heads a busy week of deals that has seen J&J agree to pay $438m for Omrix and India’s Sun further its presence in the US narcotic APIs sector through the purchase of Chattem Chemicals.
Cost cutting has sustained pharma profits in the faltering global economy, however top executives are starting to realise that reducing R&D capacity may not have been the smartest move in an era of weak pipelines and impending patent expiry, according...
Robert Sexauer, CEO of biopharmaceuticals group RCP Therapeutics, says the R&D investment deal signed with FirstPoint Biotech shows the attractiveness of the firm’s nano-medical pipeline, particularly given the current economic climate.
Eli Lilly has agreed to acquire ImClone for $6.5bn and in doing so appears to have snatched the biotech away from Bristol-Myers Squibb (BMS), which first tabled a bid back in July.
Teva and Kowa have set their sights on Japan’s $4.6bn (€3.1bn) generics market with their development and manufacturing joint venture Teva-Kowa Pharma.
Sanofi-Aventis’ €1.8bn ($2.6bn) offer for Czech generics firm Zentiva has been unanimously accepted by the latter firm’s board after four months of wrangling that has seen the bid increase by 9.5 per cent.
The Tel-Aviv District Court has found in favour of Sun Pharmaceuticals in its long running struggle to acquire Israeli drug and pharmaceutical ingredient maker Taro Pharmaceutical Industries.
US protein manufacture and development services provider American Peptide Company (APC) says that its parent company, Ito Life Sciences (ILS), is to be acquired by fellow Japanese firm Otsuka Chemical.
Brookwood Pharmaceuticals, a subsidiary of SurModics, has acquired the exclusive rights to all pharmaceutical applications of PharmaSol’s nanostructured lipid carrier (NLC) technology.
UK-based Sinclair Pharmaceuticals has entered into a manufacturing
and distribution agreement with Wockhardt, an Indian pharmaceutical
and biotech company.
Three of India´s large pharmaceutical manufacturers, Dr Reddy's,
Ranbaxy Laboratories and Shilpa Medicare have just announced new
merger and acquisition (M&A) deals.
